I think that most of the impact of the estrogen controversy is over by now, it has impacted sales, but that should be in the price. It is a little over priced here and there is a worrisome gap to ($18/20) to fill, but I think that that filling may wait till later this summer. I am out right now, but am watching for RSI to drop a little more and see if the $20 area will hold or not.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.